Sector · 13F · Q2 2026 · portfolios as of June 30, 2026
Health Care: what concentrated managers hold, add and drop (Q2 2026)
Health Care averages 15.1% of concentrated managers' 13F portfolios at the end of Q2 2026 (14.8% the previous quarter). They hold stocks of 663 companies in the sector; the largest combined position is Revolution Medicines.
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Weight of Health Care in the portfolios, 20 quarters
Q2 2026: 15.1%
Largest holdings
By combined value in concentrated managers' portfolios.
- 1Revolution MedicinesRVMD30 managers$8.9 bn
- 2DavitaDVA4 managers$6.5 bn
- 3UnitedHealth GroupUNH73 managers$6.4 bn
- 4DanaherDHR64 managers$5.8 bn
- 5Thermo Fisher ScientificTMO84 managers$5.4 bn
- 6Ascendis Pharma A/SASND14 managers$4.5 bn
- 7HumanaHUM18 managers$4.1 bn
- 8Madrigal PharmaceuticalsMDGL9 managers$4.0 bn
- 9IncyteINCY5 managers$3.5 bn
- 10Eli LillyLLY100 managers$3.5 bn
Held by the most managers
By number of concentrated managers holding it.
- 1Johnson & JohnsonJNJ4 opened · 4 exited · 14 added, 35 trimmed118was 117
- 2Eli LillyLLY14 opened · 2 exited · 27 added, 27 trimmed100was 88
- 3Thermo Fisher ScientificTMO6 opened · 8 exited · 28 added, 24 trimmed84was 85
- 4UnitedHealth GroupUNH9 opened · 9 exited · 11 added, 32 trimmed73was 73
- 5AbbVieABBV5 opened · 3 exited · 10 added, 11 trimmed69was 67
- 6MerckMRK1 opened · 1 exited · 10 added, 15 trimmed69was 68
- 7Abbott LaboratoriesABT4 opened · 3 exited · 16 added, 16 trimmed64was 63
- 8DanaherDHR6 opened · 9 exited · 19 added, 22 trimmed64was 67
- 9PfizerPFE4 opened · 5 exited · 5 added, 16 trimmed54was 55
- 10StrykerSYK6 opened · 4 exited · 13 added, 20 trimmed54was 52
Stocks most managers added
Net change in managers over the quarter, and from how many to how many. From 0 to many is usually an IPO.
- 1Eli LillyLLY14 opened · 2 exited · 27 added, 27 trimmed+1288 → 100
- 2Parabilis MedicinesPBLS11 opened · 0 exited · 0 added, 0 trimmed · nobody held it the previous quarter+110 → 11
- 3Editas MedicineEDIT9 opened · 0 exited · 1 added, 0 trimmed+91 → 10
- 4Sagimet BiosciencesSGMT8 opened · 0 exited · 0 added, 0 trimmed+83 → 11
- 5Aura BiosciencesAURA7 opened · 0 exited · 3 added, 0 trimmed+73 → 10
- 6Research Alliance Corporation IIIRACC7 opened · 0 exited · 0 added, 0 trimmed · nobody held it the previous quarter+70 → 7
- 7Definium TherapeuticsDFTX6 opened · 1 exited · 5 added, 3 trimmed+610 → 16
- 8Achieve Life SciencesACHV6 opened · 0 exited · 0 added, 0 trimmed · nobody held it the previous quarter+60 → 6
- 9Veeva SystemsVEEV8 opened · 3 exited · 7 added, 9 trimmed+524 → 29
- 10Enliven TherapeuticsELVN5 opened · 0 exited · 4 added, 4 trimmed+511 → 16
Stocks most managers dropped
Net change in managers over the quarter, and from how many to how many.
- 1ZoetisZTS6 opened · 13 exited · 8 added, 13 trimmed−939 → 30
- 2Boston ScientificBSX7 opened · 16 exited · 10 added, 7 trimmed−834 → 26
- 3IconICLR2 opened · 8 exited · 7 added, 5 trimmed−624 → 18
- 4Compass TherapeuticsCMPX1 opened · 7 exited · 3 added, 1 trimmed−611 → 5
- 5Fulcrum TherapeuticsFULC2 opened · 8 exited · 0 added, 0 trimmed−68 → 2
- 6Becton, DickinsonBDX1 opened · 6 exited · 6 added, 15 trimmed−533 → 28
- 7CVS HealthCVS0 opened · 4 exited · 5 added, 8 trimmed−523 → 18
- 8UroGen PharmaURGN0 opened · 5 exited · 2 added, 3 trimmed−513 → 8
- 9Crinetics PharmaceuticalsCRNX0 opened · 5 exited · 3 added, 1 trimmed−510 → 5
- 10Agios PharmaceuticalsAGIO0 opened · 5 exited · 2 added, 0 trimmed−59 → 4
Insider buying
Open-market purchases reported on Form 4, last 180 days.
- 1Kodiak SciencesKOD1 buyer · 7 managers$157M
- 2Artiva BiotherapeuticsARTV1 buyer · 6 managers$109M
- 3Summit TherapeuticsSMMT3 buyers · 5 managers$102M
- 4GeneDx HoldingsWGS2 buyers · 8 managers$93.1M
- 5KardiganKARD1 buyer · 4 managers$70.0M
- 6MapLight TherapeuticsMPLT1 buyer · 4 managers$65.5M
- 7Anteris Technologies GlobalAVR1 buyer · 5 managers$40.5M
- 8CG OncologyCGON1 buyer · 9 managers$24.8M
- 9Rapport TherapeuticsRAPP7 buyers · 7 managers$22.0M
- 10Viridian TherapeuticsVRDN1 buyer · 10 managers$20.0M
With holders above 5%
Companies in the sector with active 13D filings or holders reporting more than 5% (13D/13G).
- 1StrykerSYK54 managers1 above 5%1 with a 13D
- 2AbivaxABVX28 managers2 above 5%1 with a 13D
- 3Dianthus TherapeuticsDNTH21 managers5 above 5%2 with a 13D
- 4Disc MedicineIRON19 managers3 above 5%2 with a 13D
- 5HCA HealthcareHCA17 managers2 above 5%1 with a 13D
- 6Trevi TherapeuticsTRVI17 managers4 above 5%1 with a 13D
- 7Cogent BiosciencesCOGT16 managers3 above 5%1 with a 13D
- 8Enliven TherapeuticsELVN16 managers6 above 5%1 with a 13D
- 9Mirum PharmaceuticalsMIRM16 managers4 above 5%1 with a 13D
- 10CelcuityCELC15 managers6 above 5%2 with a 13D
How it is calculated
A sector's weight. For each concentrated manager we add up the weight of its positions in that sector within its 13F portfolio, then average across all of them. Every manager counts the same, whatever its size: it is not the share of total money. Stocks we could not classify weigh 2.7%; with them, the weights add up to 100%.
Where each company's sector comes from. From the industry code (SIC) the company reports to the SEC, mapped to eleven sectors with a published table, plus a short list of manual corrections. See the table.
How managers are counted. For each stock, how many concentrated managers held it at the end of the previous quarter and how many at the end of this one. A company that went public in the quarter goes from 0 to many: that is why both figures are shown, not just the difference. Who the concentrated managers are.
It is a snapshot of a quarter that has already closed: portfolios as of June 30, 2026, public by August 14, 2026. A 13F does not include short positions, bonds, cash or stocks not listed in the United States. Research information; not investment advice.